AI-Powered Biomarker discovery: Precision Diagnostics in Organ Transplant Risk Assessment

Join us on Tuesday, April 29th, 3pm CEST, for an in-depth exploration of the importance of AI-powered biomarker discovery and precision diagnostics.

Join us on Tuesday, April 29th, 3pm CEST, for an in-depth exploration of the importance of AI-powered biomarker discovery and precision diagnostics. 

As the volume and complexity of biomedical data continue to grow, extracting actionable insights that directly impact patient outcomes remains a critical challenge for the life sciences sector. The integration of AI in bioinformatics is transforming how biomarkers are discovered and developed.

In this interactive webinar, the team of data scientists will be complemented by a clinician to provide perspective on how these advancements are clinically relevant and applicable with the goal of improving  patient care.

Why attend?

  • Discover how AI-powered bioinformatics and multi-omics integration are revolutionizing biomarker discovery.
  • Learn from a real-world case study (Tutivia™) how advanced RNA signature analysis and machine learning can improve risk stratification and support clinical decision-making for patient care.
  • See how next-generation platforms like Bio|Verse™ empower researchers to seamlessly analyze, integrate, and visualize complex biomedical data, accelerating the journey from data to actionable insights.

Expert speakers include:

  • Moderator: Alexander Koch, PhD, Team Lead Bioinformatics, BioLizard
  • Volodimir Olexiouk, PhD, Director Services & Solutions, BioLizard
  • Patti Connolly, COO, Verici Dx
  • Nehal Doshi, Principal Bioinformatics Scientist, Verici Dx
  • Zahraa Hajjiri, Medical Director of Transplant Nephrology at the University of Illinois at Chicago

Don’t miss this opportunity to explore how AI-powered biomarker discovery is transforming precision medicine and diagnostics and how it is shaping the future of healthcare innovation.

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

In oncology, the drug development path is unique: Phase 0 and Phase I trials are typically conducted in patients rather than healthy volunteers, allowing for early assessment of efficacy and patient selection alongside safety. Yet, even with this early clinical insight, many cancer drugs show promise in the lab but fail to transition effectively into the clinic. This often happens because, while we verify that a drug’s target is present, we frequently overlook its context, specifically its location, the surrounding microenvironment, and its interaction with neighboring cells. By revisiting real-world examples of discontinued trials, this post explains why understanding the “where” is just as critical as the “what”, and how spatial biology is positioning itself as a valuable avenue for validating clinical potential.

Why bioinformatics workflows require experienced software engineers

Bioinformatics pipelines break for the smallest reasons: package updates, shifting dependencies, or “it only works on my machine.” This post explains why experienced software engineers and DevOps practices (Git, CI/CD, IaC) are essential to keep workflows reproducible, stable, and scalable.